Michael Bishara, MD
Addiction Medicine · Riverside, CANPI 1144311044
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 113 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $844, 2.4 times the $355 reported in 2019.
Across 113 payments — averaging $19.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$447
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$322
- Alkermes, Inc.$281
- Braeburn Inc.$247
- Pfizer$207
- AbbVie$155
- plus $496 from 16 others
What the payments were for
- Food & beverage$2,13999%
- Education$161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Indivior Inc. | 29 | $447 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $322 |
| Alkermes, Inc. | 12 | $281 |
| Braeburn Inc. | 12 | $247 |
| Pfizer | 12 | $207 |
| AbbVie(2 entities) | 9 | $155 |
| Eisai Inc. | 5 | $90 |
| Vanda Pharmaceuticals Inc. | 3 | $77 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $44 |
| Orexo US, Inc. | 2 | $44 |
| Gilead | 2 | $33 |
| Hologic Sales And Service, LLC | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 2 | $24 |
| Lilly USA, LLC | 1 | $23 |
| Masimo Corporation | 1 | $19 |
| Titan Pharmaceuticals, Inc. | 1 | $17 |
| Merck | 1 | $17 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
| Valinor Pharma, LLC | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
| MDD US Operations, LLC | 1 | $12 |
How this compares
$2,154 in reported general payments places this provider in the 85th percentile of 190 addiction medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 293 | $58,351 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 22 | $20,223 |
| EliquisApixaban | 28 | $17,669 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 12 | $8,063 |
| JanuviaSitagliptin Phosphate | 12 | $6,284 |
| Paliperidone ErPaliperidone | 21 | $5,334 |
| Lurasidone Hcl | 12 | $3,064 |
| Buprenorphine Hcl | 71 | $2,842 |
| KlonopinClonazepam | 11 | $2,291 |
| Aripiprazole | 38 | $1,774 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 47 | $1,362 |
| Celecoxib | 22 | $1,220 |
| Gabapentin | 62 | $1,197 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $878 |
| Naltrexone Hcl | 19 | $780 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Indivior Inc.Suboxone | $447 | $20,22322 claims |
| PfizerEliquis | $207 | $17,66928 claims |
| Orexo US, Inc.Zubsolv | $44 | $8,06312 claims |
| MerckJanuvia | $17 | $6,28412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 190 addiction medicine providers in California.
Other addiction medicine in Riverside
- Tipu KhanVentura$262K
- Anthony AlbaneseMather$135K
- Matthew TorringtonCulver City$77K
- Kenneth StarrArroyo Grande$64K
- Drew PinskySouth Pasadena$60K
- Mark HonzelBeverly Hills$27K
- Bryan HylerVista$17K
- Abraham MalkinLos Angeles$12K
- Jonathan ReitmanBeverly Hills$11K
- Caleb LuskSan Pedro$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.